Q1 2026 Results Show Increased Net Loss and Going Concern Warning Despite Improved Working Capital
BHST is trading near its 52-week low of $3.57 (14% above the low).
Summary
BioHarvest Sciences reported Q1 2026 results with increased revenues but a higher net loss, alongside a 'going concern' warning, though liquidity improved with positive working capital and loan repayments.
Key Events · Earnings and Guidance · BHST
-
Q1 2026 Financial Performance
Revenues increased 8% year-over-year to $8.5 million, but the net loss widened to $2.6 million from $2.3 million in Q1 2025. Loss per share improved to $(0.11) from $(0.13) due to a higher share count.
-
Going Concern Warning Issued
The company disclosed 'substantial doubt' about its ability to continue as a going concern due to a history of operating losses and the need for continued investment, despite management's belief in adequate resources and access to capital markets.
-
Improved Liquidity and Debt Repayment
Net working capital significantly improved to $18.7 million positive as of March 31, 2026, compared to a negative $9.2 million a year prior. The company also fully repaid its short-term 16% and 20% loan facilities during the quarter.
-
Cash Position Decreased
Cash and cash equivalents decreased by $3.8 million during Q1 2026, ending the period at $19.1 million, reflecting ongoing cash usage from operating and investing activities.
Analysis · BHST · Life Sciences
This filing reveals BioHarvest Sciences' first-quarter 2026 financial results, which include an 8% increase in revenues but also a higher net loss. Critically, the company has issued a 'going concern' warning, indicating substantial doubt about its ability to continue operations without additional financing, despite management's assessment of adequate resources. While net working capital significantly improved year-over-year and short-term high-interest loans were repaid, the continued net loss and a $3.8 million decrease in cash and cash equivalents during the quarter highlight ongoing financial challenges and the need for future capital.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1059 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHST was trading at $4.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92M. The 52-week trading range was $3.57 to $12.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.